Daré Bioscience, Inc. (NASDAQ:DARE) Sees Large Decline in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) saw a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 35,400 shares, a drop of 9.7% from the August 31st total of 39,200 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 46,900 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th.

Daré Bioscience Stock Up 0.5 %

Shares of NASDAQ DARE traded up $0.02 during midday trading on Friday, hitting $3.27. The stock had a trading volume of 10,490 shares, compared to its average volume of 46,369. Daré Bioscience has a 1 year low of $3.05 and a 1 year high of $7.56. The company has a market capitalization of $27.54 million, a PE ratio of -0.85 and a beta of 1.39. The stock has a 50 day simple moving average of $3.44 and a 200-day simple moving average of $4.29.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $2.09. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.60 million. As a group, analysts expect that Daré Bioscience will post -0.27 earnings per share for the current fiscal year.

Institutional Trading of Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC boosted its stake in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the SEC. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.